Ì«Ñô¼¯ÍŹÙÍø

English Ì«Ñô¼¯ÍŹÙÍø¼¯ÍÅÆóÒµÓÊÏä

MEBOÔÚ¼¤¹âìî°ß´´ÃæÖеÄÖÎÁÆ×÷ÓÃ

2012Äê-07ÔÂ-23ÈÕ ÈªÔ´£º

ÁøÖÝÊÐÁøÌúÖÐÐÄÒ½ÔºÕûÐÎÍâ¿Æ  Ö쵤±ë  ÇØºèÖ¾  Áú  ê¿

¡¾ÕªÒª¡¿Ä¿µÄ  ÊÓ²ìÌ«Ñô¼¯ÍŹÙÍøÊªÈóÉÕÉ˸ࣨMEBO£©¶Ô¼¤¹âìî°ßÊõºó´´ÃæÓúºÏµÄЧ¹û¡£ÒªÁì  ½«120Àý¼¤¹âìî°ßÊõºóµÄ»¼Õߣ¬Ëæ»ú·ÖΪÖÎÁÆ×éºÍ±ÈÕÕ×飬¸÷60Àý£¬ÖÎÁÆ×éÊõºóÔÚ´´ÃæÍ¿Ä¨MEBO£¬ÌìÌì4´Î~6´Î£¬¼á³Ö´´Ãæ³ÊʪÈó״ֱ̬ÖÁ´´ÃæÓúºÏ £»±ÈÕÕ×é´´ÃæÍ¿ÒÔºìÃ¹ËØÈí¸à£¬ÌìÌì4´Î~6´Î£¬Ö±ÖÁ´´ÃæÓúºÏ¡£ÊÓ²ì2×éÔÚÊõºóµÄֹʹЧ¹û¡¢´´ÃæÓúÊÊʱ¼ä¡¢É«ËØÀä¾²¼°ÆäÏûÍ˵ȷ½ÃæµÄÁÆÐ§¡£Ð§¹û  ÖÎÁÆ×éÊõºóÌÛÍ´ºÍ´´ÃæÓúÊÊʱ¼äÓë±ÈÕÕ×é½ÏÁ¿ÓÐÏÔÖø²î±ð£¨P£¼0.01£© £»Êõºó´´ÃæÉ«ËØÀä¾²ÇéÐÎÁ½×éÏà±È²î±ðÎÞͳ¼ÆÑ§ÒâÒ壬µ«ÔÚ´´ÃæÉ«ËØÀä¾²µÄÏûÍËʱ¼äÉÏ£¬ÖÎÁÆ×é±È±ÈÕÕ×éÏÔ×ÅËõ¶Ì£¬²î±ðÏÔÖø£¨P£¼0.01£©¡£½áÂÛ  MEBO¶Ô¼¤¹âìî°ßÊõºó´´Ãæ¾ßÓпìËÙֹʹ¡¢Ëõ¶Ì´´ÃæÓúÊÊʱ¼ä¡¢Ôö½øÉ«ËØÀä¾²ÏûÍ˵Ä×÷Óã¬ÊÇ´¦Öóͷ£¼¤¹âÊõºó´´ÃæµÄÀíÏëÒªÁì¡£
¡¾Òªº¦´Ê¡¿Ì«Ñô¼¯ÍŹÙÍøÊªÈóÉÕÉ˸à £»¼¤¹â £»ìî°ß £»ºìÃ¹ËØÈí¸à
¡¾Abstract¡¿Objective  To observe the therapeutic effect of MEBO Wound Ointment £¨MEBO£©in the treatment of surgical sites after spot area laser therapy. Method The 120 patients after spot area laser therapy were randomly and evenly divided into treatment group and control group. In treatment group, MEBO Wound Ointment was administered after surgery for 4-6 times a day, keeping the surgical sites moist until wound healing; In control group, the surgical sites were applied with erythromycin ointment for 4-6 times a day until healing. And then, the indicators of therapeutic effects, such as the postoperative pain relief, wound healing days, pigment deposition and fading were observed in two groups. Results Compared to control group, the postoperative pain relief and wound healing days in treatment group had significant differences(P£¼0.01); pigment deposition in two groups showed no statistical difference, but the fading time of pigment in treatment group was significantly shorter than that in control group (P£¼0.01). Conclusion MEBO Wound Ointment in the treatment of surgical wounds after spot area laser therapy is effective on rapid relief of pain, shortening healing time and promoting pigment fading, thus is an ideal therapeutic approach in the treatment of surgical wounds after laser therapy.
¡¾Key words¡¿MEBO Wound Ointment; Laser; Spot area surgery; Erythromycin ointment
½üÄêÀ´£¬Ó¦Óü¤¹âìî°ßµÄÖÎÁÆÒªÁìÒѾ­ÆÕ±éÓ¦Óã¬ÓÈÆäÒÔYAG¼¤¹âìî°ßÒªÁìΪ´ú±í£¬Ð§¹ûÈ·ÇС£ÖÎÁÆÔ­ÀíÊÇʹÓü¤¹âµÄÑ¡ÔñÐÔ¹âÈÈ×÷ÓÃÖÎÁÆÉ«Ëز¡±ä£¬ÓŵãÊÇÄÜ×èÖ¹´ó²¿·ÖƤ·ô×éÖ¯µÄËðÉË´Ó¶ø²»Ò×·ºÆðñ£ºÛ¡£µ«¼¤¹âÖÎÁƺó´´ÃæµÄ´¦Öóͷ£Ò²ºÜÊÇÒªº¦£¬ÈôÊÇ´´ÃæÓÃÒ©²»µ±£¬²»µ«ÑÓÉìÓúÊÊʱ¼ä£¬ÉõÖÁ»áÔì³ÉѬȾ£¬µ¼ÖÂñ£ºÛÐγÉ¡£ÏÖÔÚ¼¤¹âÖÎÁƺóµÄ´´ÃæÓÃÒ©½ÏÁ¿ÔÓÂÒ£¬ÓÐÍâÍ¿µâ·ü¡¢¿µ¸´Ð¡¢Ë«ÑõË®µÈÒ©Ë®£¬Ò²ÓÐÍâÍ¿ºìÃ¹ËØ¡¢½ðÃ¹ËØ¡¢ÉÕÉ˸àµÈÖÖÖÖÒ©¸àÕß¡£ÎÒ¿ÆÓÚ1996Äê10ÔÂÖÁ1999Äê10Լ䣬¶Ô120Àý¼¤¹âìî°ßÊõºó´´ÃæµÄ´¦Öóͷ£»®·Ö½ÓÄÉMEBOºÍºìÃ¹ËØÈí¸àͿĨ´´Ã棬²¢¾ÙÐÐÁËÁÆÐ§ÊÓ²ìºÍ½ÏÁ¿ÆÊÎö¡£ÏÖ±¨µÀÈçÏ£º
1.×ÊÁÏÓëÒªÁì
1.1.Ò»Ñùƽ³£×ÊÁÏ
½«¼¤¹âìî°ßÖÎÁƵÄ120Àý»¼Õߣ¬Ëæ»ú·ÖΪÁ½×飺ÖÎÁÆ×éºÍ±ÈÕÕ×飬¸÷60Àý¡£ÖÎÁÆ×é½ÓÄÉÌ«Ñô¼¯ÍŹÙÍøÊªÈóÉÕÉ˸ࣨMEBO£©ÔËÓÃʪÐÔÒ½Ò©ÊÖÒÕÖÎÁÆ £»±ÈÕÕ×é½ÓÄɺìÃ¹ËØÈí¸àÍâÍ¿£¬Á½×é¾ù½ÓÄÉ´´ÃæÌ»Â¶ÁÆ·¨ÖÎÁÆ¡£Ì«Ìïðë58Àý£¬È¸°ß37Àý£¬¿§·È°ß25Àý £»Å®ÐÔ98Àý£¬ÄÐÐÔ22Àý £»ÄêËê14Ëê~46Ë꣬ƽ¾ù28.5Ë꣬ÉíÌ念½¡£¬¾ùΪÃÅÕﻼÕß¡£
1.2.ÒªÁì
½ÓÄÉͨÀýµâ¾Æ¡¢¾Æ¾«Ïû¶¾´´Ã棬ÊõÇø¾Ö²¿ÓÃ0.5%Àû¶à¿¨ÒòÐÄÀíÑÎË®ÈÜÒº½þÈóÂé×í£¬È»ºóÓÃË«²¨³¤Âö³åµ÷Q¼¤¹â£¨³¤´º¹â»úËùÉú²úµÄYQ400-A/BI£©¾ÙÐÐÖÎÁÆ£¬¼¤¹âÁÙ´²²ÎÊýµÄÉ趨ÒÀ¾Ý²¡±äµ÷½â£¬¼¤¹âµÄ²¨³¤¡¢ÄÜÁ¿Ãܶȡ¢¹â°ß¡¢Âö¿íºÍƵÂÊӦƾ֤»¼ÕßµÄÄêËê¡¢·ôÉ«¡¢²¡±ä²¿Î»¡¢²¡±äÑÕÉ«¾ÙÐÐÉ趨 £»±¾¼¤¹âÓÐ532 nmºÍ1064 nmÁ½¸ö²¨³¤¡£¼¤¹âÖÎÁÆÍê±Ïºó£¬Æ¾Ö¤Æ¤·ôԭλÔÙÉúÒ½ÁÆÊÖÒÕ¾ÙÐд´Ãæ´¦Öóͷ££º²»Ê¹Óô̼¤ÐÔÏû¶¾Òº£¬ÓÃÎÞ¾úÐÄÀíÑÎˮϴåªÇå½à¡£È»ºóÖÎÁÆ×é½ÓÄÉÌ«Ñô¼¯ÍŹÙÍøÊªÈóÉÕÉ˸àÍâÍ¿£¬¿ÉÓÃѹÉà°å»òÃÞÇ©½«ÆäÔȳÆÍ¿Ä¨ÓÚ´´Ã棬ºñ1 mm~2 mm£¬4 h~6 h»»Ò©1´Î£¬Ã¿´ÎͿҩǰ½«´´Ãæ²ÐÁôµÄÒ©ÎïºÍÉøÍ¸Îïɨ³ýÇå½à£¬¿ÉÏÈÓÃÎÞ¾úÐÄÀíÑÎˮϴ媴´Ã棬ȻºóͿ̫Ñô¼¯ÍŹÙÍøÊªÈóÉÕÉ˸࣬Ӧʱ¿Ì¼á³Ö´´Ãæ³ÊʪÈó״̬£¬±ÜÃâ´´Ãæ½áð裬ֱÖÁ´´ÃæÓúºÏ¡£±ÈÕÕ×é½ÓÄÉ1%ºìÃ¹ËØÈí¸àÍâÍ¿£¨Í¿Ò©ºñ¶È¡¢»»Ò©Ê±¼ä¡¢´´ÃæÏ´åªµÈºÍÖÎÁÆ×éÏàͬ£©£¬Ö±ÖÁ´´ÃæÓúºÏ¡£Á½×é¾ùÊÓ²ì¼Í¼´´ÃæÓúÊÊʱ¼ä¡¢ÊõºóÌÛÍ´ÇéÐΣ¬²¢Ëæ·Ã6¸öÔÂÖÁ9¸öÔ£¬ÊÓ²ì´´ÃæÉ«ËØÀä¾²ÇéÐΡ£´´ÃæÓúºÏºóÖö¸À»¼Õß×¢ÖØ·Àɹ£¬ÒÔ×èÖ¹É«ËØÀä¾²£¬Í¬Ê±·þÓÃάÉúËØc¼õÇáÉ«ËØÀä¾²¡£
1.3.ÊÓ²ìÖ¸±ê
¢Ù´´ÃæÓúÊÊʱ¼ä £»¢ÚÊõºóÌÛÍ´ £»¢ÛÉ«ËØÀä¾²¡£
1.4.ͳ¼ÆÑ§´¦Öóͷ£
Ó¦ÓÃÅÌËã»úSPSS 11.0ͳ¼ÆÈí¼þ¾ÙÐÐͳ¼ÆÑ§´¦Öóͷ££¬¼ÆÁ¿×ÊÁϾùÒÔx(_)¡ÀsÌåÏÖ£¬½ÓÄÉtÄ¥Á·²â¶¨ÆäÏÔÖøÐÔ £»¼ÆÊý×ÊÁÏÒÔÂÊÌåÏÖ£¬×é¼äµÄ½ÏÁ¿½ÓÄɦÖ2Ä¥Á·£¬P£¼0.05Ϊ²î±ðÓÐͳ¼ÆÑ§ÒâÒå¡£
2.Ч¹û
MEBO×éµÄ´´ÃæÓúÊÊʱ¼äÒÔ¼°´´ÃæÊõºóÌÛÍ´ÇéÐÎÓëºìÃ¹ËØÈí¸à×éÏà±È£¬P£¼0.01£¬ÓÐÏÔÖøÐÔ²î±ð£ºMEBOÄܹ»ÏÔ׿õÇá´´ÃæÌÛÍ´ÒÔ¼°Ôö½ø´´ÃæÓúºÏ£¨¼û±í1¡¢±í2£©¡£Á½×é´´ÃæÓúºÏºó·º×ª»úËØÀä¾²µÄ²î±ðÎÞͳ¼ÆÑ§ÒâÒ壨P£¾0.05£©£¬¿ÉÊÇ´ÓÉ«ËØÀ侲ʱ¼äµÄÏûÍËÉÏ¿´£ºMEBO×éµÄ´´ÃæÉ«ËØÀä¾²Ò»Á¬Ê±¼ä±ÈºìÃ¹ËØÈí¸à×éÏÔ×ÅËõ¶Ì£¨P£¼0.01£¬¼û±í3£©¡£

3.ÌÖÂÛ
3.1.Ôö½ø´´ÃæÓúºÏ
MEBOÊÇÒ»ÖÖ¿ò¼ÜÈí¸à¼Á£¬º¬ÓлÆÜË¡¢»Æ°Ø¡¢·äÀ¯¡¢ÂéÓ͵ÈÒòËØ£¬²»µ«ÄÜ¿¹Ñ¬È¾¡¢ìÉú¼¡¡¢»îѪ»¯ðö£¬ÎªÔ­Î»¸Éϸ°ûÔÙÉúÐÞ¸´´´Á¢Ìõ¼þ£¬Ôö½ø´´ÃæµÄÓúºÏ£¬²¢ÇÒÈí¸àÖеĦÂ-¹ÈçÞ´¼¿É¸ÄÉÆ¾Ö²¿Î¢Ñ­»·£¬¼õÇá¾Ö²¿×éÖ¯ÓÙÖÍËðÉË£¬Ê¹×éÖ¯×î´óÏ޶ȵػñµÃËÕÐÑÉú³¤£¬ÉÏÆ¤Ï¸°ûѸËÙÔöÖ³£¬´Ó¶ø´Ùʹ´´ÃæÓúºÏ[1]¡£±¾ÊµÑ鼤¹âÖÎÁƺóµÄ´´ÃæÀàËÆÓÚdz¢ò¶ÈÉÕÌÌÉË´´Ã棬¶øMEBOÔÚÉÕÉË»òÌÌÉËµÈÆ¤·ôËðÉËÖÐÒѾ­»ñµÃ¼«ÎªÆÕ±éµÄÓ¦Óã¬ÇÒЧ¹ûÓÅÒ죬ÊÇÖÎÁÆÉÕÉË»òÌÌÉËµÈÆ¤·ôËðÉ˵ÄÊ×Ñ¡ÓÃÒ©£¬ÒÔÊǽ«MEBOÔËÓÃÔÚ¼¤¹âìî°ßÊõºóµÄ´´ÃæÊÇÓÐÒÀ¾ÝµÄ¡£ÓÉÓÚMEBOÔËÓÃÆÕ±éÇÒ±»Ò»Ö±µØÍÚ¾ò£¬Òò´ËMEBOÔÚÕûÐÎÃÀÈÝרҵҲ»ñµÃºÜºÃµÄÓ¦Óá£È磺CO2¼¤¹âÖÎÁÆÆ¤·ô»òð¤Ä¤ÉϵÄðà»ò׸ÉúÎïµÄ´´Ãæ[2] £»Ë«²¨³¤Âö³åµ÷QND:YAG¼¤¹âÖÎÁÆ»úϴü¡¢ÑÛÏß¡¢ÎÆÉí¡¢Ãæ²¿È¸°ßµÈ´´Ãæ[3] £»ÒÔ¼°Ö²Æ¤ºó¹©Çø´´ÃæµÄÖÎÁƵȵÈ£¬¶¼Ö¤ÊµMEBO¶ÔƤ·ô´´ÉËÓÐÓÅÒìµÄÓúºÏ×÷Óá£
3.2.Ôö½øÉ«ËØÀä¾²µÄÏûÍË
ÑÇÖÞÈËÔÚÆ¤·ôÊÜËðºóÈÝÒ×·º×ª»úËØÀä¾²£¬µ«´ó¶à¿ÉÒÔ×ÔÐÐÏûÍË£¬Ê±¼äÊÇ·Ç·×Æç£¬Ò»Ñùƽ³£Îª2¸öÔÂ~6¸öÔ£¬ÉÙÊý»¼ÕßÄÑÒÔÉõÖÁºã¾Ã²»ÍË£¬ÊÇÆ¤·ôÖÎÁÆ£¨Ä¥Ï÷£¬¼¤¹âµÈ£©µÄ³£¼û²¢·¢Ö¢£¬»ÆÖÖÈ˸üΪÏÔ×Å¡£Æ¤·ôÔâµ½ÖÖÖÖ´´ÉË£¨²ÁÉË¡¢ÉÕÌÌÉË¡¢Ä¥Ï÷¡¢¼¤¹âµÈ£©ÓúºÏºó£¬ÓÐ85%µÄ»¼Õß·º×ª»úËØÀä¾²[4]£¬Ò²ÓÐÉÙÉÙÊý»¼ÕßÔÚ´´ÃæÓúºÏÈ´ÁôÏÂÉ«ËØÍÑʧ¡£É«ËØÀä¾²µÄ»úÖÆÏÖÔÚÉÐδÍêÈ«Ã÷Îú£¬µ«´Ó±¾ÁÙ´²Ñо¿¿ÉÒÔ¿´µ½£ºÁ½×éÖÎÁÆÒªÁì¶Ô´´ÃæÓúºÏºó·º×ª»úËØÀä¾²µÄ²î±ðËäÎÞͳ¼ÆÑ§ÒâÒ壬µ«MEBO×éµÄ´´ÃæÉ«ËØÀä¾²ÏûÍËʱ¼ä±ÈºìÃ¹ËØÈí¸à×éÏÔ×ÅËõ¶Ì¡£ÎÒÃÇ˼Á¿É«ËØÀä¾²¿ÉÄÜÓë´´ÃæµÄÓúÊÊʱ¼äÓйØ£¬´´ÃæÔ½ÔçÓúºÏ£¬²¢ÇÒÓúºÏÖÊÁ¿Ô½ºÃ£¬É«ËØÀä¾²µÄÏûÍ˾ÍÔ½¿ì¡£ÁíÍ⣬´´ÃæÉ«ËØÀä¾²ÏûÍËÓëMEBOÒòËØÊÇ·ñÓйØ£¬Óдý½øÒ»²½ÇóÖ¤¡£
3.3.»º½â´´ÃæÌÛÍ´
Àû¶à¿¨Òò£¨¼ÓÉöÉÏÏÙËØ£©µÄ¾ÖÂéЧ¹ûÒ»Ñùƽ³£»áÒ»Á¬1 h~2 h£¬±ÈÕÕ×éÔÚ¾ÖÂéЧ¹ûɨ³ýºó»áÓÐ¶ÌÆÚÀ±Í´¸ÐÊÜ£¨5 min~30 min£©£¬ºìÃ¹ËØÈí¸àµÄ´Ì¼¤×÷Óþ­³£ÒýÆð´ó¶¼»¼ÕßÖÎÁÆÇøÆ¤·ô×ÆÍ´£¬¶øÖÎÁÆ×éÍâͿ̫Ñô¼¯ÍŹÙÍøÊªÈóÉÕÉ˸àºó£¬³ý7ÀýÓÐ¶ÌÆÚµÄÀ±Í´¸ÐÊÜÍ⣬ÆäÓà¾ùÎÞÌÛÍ´¸ÐÊÜ¡£²¢ÇÒ¸ÐÊÜ¶ÌÆÚÌÛÍ´µÄ7Àý»¼Õߣ¬Ò²ÔÚÍâÓÃÌ«Ñô¼¯ÍŹÙÍøÊªÈóÉÕÉ˸àÔ¼10 minºóÌÛÍ´ÏûÊÅ£¬¾­ÆÊÎöºó·¢Ã÷ÊÇÒòÕâ7Àý»¼ÕßÉ«°ßÃæ»ý½Ï´ó£¬¼¤¹âÖÎÁÆÊ±¼ä½Ï³¤£¬Áè¼Ý2 h£¬ÒѾ­ÓÉϳ¡ÂéÒ»Á¬Ê±¼ä£¬´´Ãæ·ºÆðÀ±Í´¸ÐÊÜ£¬µ«¾­ÓÉÍâͿ̫Ñô¼¯ÍŹÙÍøÊªÈóÉÕÉ˸àºóÌÛÍ´»º½â£¬ÕâÊÇÓÉÓÚÌ«Ñô¼¯ÍŹÙÍøÊªÈóÉÕÉ˸à¾ßÓÐֹʹ×÷ÓÃ[5]£¨Ô¼Ðè10 min²Å»ªÊ©Õ¹Ö¹Í´×÷Óã©¡£MEBOֹʹµÄ»úÀí£º£¨1£©MEBOÓë´´ÃæµÄ»µËÀ±À½â×éÖ¯±¬·¢»¯Ñ§·´Ó¦£¬¶øÓëÓлîÁ¦µÄ×éÖ¯²»±¬·¢·´Ó¦£¬·´¶ø¿ÉÔÚÆäÉÏÐγɱ £»¤Ä¤£¬± £»¤Ì»Â¶µÄÉñ¾­Ä©ÉÒ£¬µÖ´ïֹʹЧ¹û £»£¨2£©Ó¦ÓÃMEBOºó¿Éʹ´´ÃæÊªÈó£¬ÇÒ¿¿½üÐÄÀíÇéÐΣ¬×èÖ¹Á˸ÉÔï½áðèµÄËõ¶Ì¶øÇ£À­´´Ãæ×éÖ¯ËùÖµÄÌÛÍ´ £»£¨3£©MEBOµÄ± £»¤´´ÃæºÍÒýÁ÷µÈ×÷Ó㬼õÇáÁË´´ÃæµÄÑ×Ö¢·´Ó¦£¬Ê¹¾Ö²¿×é֯ˮÖ×¼õÇᣬ¶ÔÉñ¾­Ä©ÉÔµÄեȡºÍ´Ì¼¤ïÔÌ­£¬ÌÛÍ´×ÔÈ»¼õÇá¡£
²Î¿¼ÎÄÏ×
[1]ÐìÈÙÏé.ÉÕÉËÒ½ÁÆÊÖÒÕÀ¶Æ¤±¾£¨µÚ1¾í£©[M].ÖйúÒ½Ò©¿Æ¼¼³öÊéÉ磬2000£º45~46.
[2]Ñî¾ü£¬»Ý½Ý£¬Ðìºì. MEBOÓëºìÃ¹ËØÑÛ¸àÖÎÁÆCO2¼¤¹â´´ÃæµÄÁÆÐ§ÆÊÎö[J]. ÖйúÉÕÉË´´ÑñÔÓÖ¾,2008,20(4):314~316.
[3]ÀîÐËÍú£¬Áõ²ßÀø£¬ÒóÓ£¬µÈ. MEBOÔÚ¼¤¹âÃÀÈÝÖÎÁÆÖеÄÓ¦ÓÃ[J]. ÖйúÉÕÉË´´ÑñÔÓÖ¾,2007,19(1):72~74.
[4]Plensdorf S,Martinez J.Common pigmentation disorders[J]. American Family Physician,2009,79(2):21~23.
[5]Íõ¹úÔ¨£¬ÕŽðÁú.MEBOÍŽáºì¹âÕÕÉäÖÎÁÆÉÕÉË´´ÃæµÄÁÆÐ§ÊÓ²ì[J].ÖйúÉÕÉË´´ÑñÔÓÖ¾£¬2009£¬21£¨4£©£º270~271.

ÍøÕ¾µØÍ¼